Use of recombinant apolipoproteins in vascular diseases: the case of apoA-I.
Apolipoprotein (apo) A-I, because of its anti-atherogenic properties, represents a powerful approach to the management of vascular diseases. Infusion of apoA-I-containing synthetic high-density lipoprotein (HDL) inhibits atherosclerosis progression or prevents restenosis in experimental animals, and apoA-I liposomes are capable of stimulating reverse cholesterol transport in humans. Moreover, many experimental studies have been conducted with a molecular variant of apoA-I, apoA-I(Milano), characterized by a prolonged residence time in plasma and improved function, which may offer an even better approach to the therapeutic handling of arterial disease.
Chiesa
Giulia
G
Department of Pharmacological Sciences, University of Milan, Italy. Giulia.Chiesa@unimi.it
Sirtori
Cesare R
CR
D000818:Animals; D016632:Apolipoprotein A-I / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D014652:Vascular Diseases / Q000188:drug therapy*
D016632:Apolipoprotein A-I; D008074:Lipoproteins; D011994:Recombinant Proteins